DWTX READ THE FULL DWTX RESEARCH REPORT Business Update Phase 2 Long COVID Results Expected Soon Dogwood Therapeutics, Inc.

Compass Pathways' latest update reveals extended trial timelines, staff cuts, and financial concerns, raising questions about ...

Running Phase 3 trials is costly, and $200 million may not ... which the company never reported on. As shown in the table below, the MMSE scores were only used to differentiate patients at the ...

The PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial is 100% enrolled; expect to report topline data for this cohort in late Q1 2025 or Q2 ...

Announced positive topline results from KARISMA-Endoxifen Phase 2 study which demonstrated that low doses of (Z)-endoxifen significantly reduced ...

Idaho murder suspect Bryan Kohberger returned to court Thursday, where his defense hopes to have the death penalty taken off ...

In Japan, clinical use is climbing faster, with about 4,500 people now on the drug. ARIA rates in Japan are half those in the U.S., which was also the case in the Phase 3 Clarity trial. Meanwhile, use ...

Bionomics Limited in Australia will soon launch phase 3 trials of the investigational oral drug, which is a negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor.

CEO Roberto Iacone admitted in an interview that the market remains tough, even for a biotech in the red-hot ADC world. But ...